Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Jul 20;17(1):313.
doi: 10.1186/s13071-024-06363-w.

Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs

Affiliations
Comparative Study

Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs

Kathryn E Reif et al. Parasit Vectors. .

Abstract

Background: Canine acaricides with rapid onset and sustained activity can reduce pathogen transmission risk and enhance pet owner experience. This randomized, complete block design, investigator-masked study compared the speed of kill of Amblyomma americanum provided by three monthly-use isoxazoline-containing products.

Methods: Eight randomized beagles per group were treated (day 0), per label, with sarolaner (combined with moxidectin and pyrantel, Simparica Trio™), afoxolaner (NexGard™), or lotilaner (Credelio™), or remained untreated. Infestations with 50 adult A. americanum were conducted on days - 7, - 2, 21, and 28, and tick counts were performed on day - 5 (for blocking), and at 4, 8, 12, 24, 48, and 72 h following treatment and subsequent infestations. Efficacy calculations were based on geometric mean live tick counts. A linear mixed model was used for between-group comparisons.

Results: On day 0, only lotilaner significantly reduced an A. americanum infestation by 12 h (43.3%; P = 0.002). Efficacy of lotilaner and afoxolaner at 24 h post-treatment was 95.3% and 97.6%, respectively, both significantly different from sarolaner (74%) (P = 0.002, P < 0.001, respectively). On day 21, at 12 h postinfestation, lotilaner efficacy (59.6%) was significantly different from sarolaner (0.0%) (P < 0.001) and afoxolaner (6.3%) (P < 0.001). At 24 h, lotilaner efficacy (97.4%) was significantly different (P < 0.001) from sarolaner and afoxolaner (13.6% and 14.9%, respectively). On day 28, at 12 h postinfestation, lotilaner efficacy (47.8%) was significantly different from sarolaner (17.1%) (P = 0.020) and afoxolaner (9.0%) (P = 0.006). At 24 h, lotilaner efficacy (92.3%) was significantly different from sarolaner 4.9% (P < 0.001) and afoxolaner (0.0%) (P < 0.001). Speed of kill for sarolaner and afoxolaner, but not lotilaner, significantly declined over the study period. Following reinfestation on day 28, neither sarolaner nor afoxolaner reached 90% efficacy by 48 h. By 72 h, sarolaner efficacy was 97.4% and afoxolaner efficacy was 86.3%. Only lotilaner achieved ≥ 90% efficacy by 24 h post-treatment and 24 h postinfestation on days 21 and 28. Time to ≥ 90% efficacy following new infestations consistently occurred 24-48 h earlier for lotilaner compared with sarolaner or afoxolaner.

Conclusions: Credelio (lotilaner) has a more rapid onset of acaricidal activity against A. americanum than Simparica Trio (sarolaner-moxidectin-pyrantel) and NexGard (afoxolaner). Only lotilaner's speed of tick kill is sustained throughout the dosing period.

Keywords: Amblyomma americanum; Afoxolaner; Canine; Credelio; Dog; Lone star tick; Lotilaner; NexGard; Sarolaner; Simparica Trio.

PubMed Disclaimer

Conflict of interest statement

K.E.R., M.W.D., and B.H.H. are paid consultants for several animal health companies including Elanco Animal Health and Boehringer Ingelheim. T.M.K. and J.C.N. are employees of Elanco Animal Health. W.G.R. and M.C.B. are paid consultants for Elanco Animal Health. J.R.J.J.C. is an Associate Editor of Parasites and Vectors and is a paid consultant for Boehringer Ingelheim. A portion of K.R.M. and C.J.S. graduate program is funded by Elanco Animal Health.

Figures

Fig. 1
Fig. 1
Mean live tick counts ± standard error of the mean (± SEM) of dogs left untreated or treated on day 0 with either Simparica Trio (sarolaner-moxidectin-pyrantel), NexGard (afoxolaner) or Credelio (lotilaner) at a timepoint (h) post-treatment and following infestations on day 21 and 28 (each infestation with 50 Amblyomma americanum). *Day 0 counts are relative to time post-treatment; day 21 and 28 counts represent time following infestations

References

    1. Swanson M, Pickrel A, Williamson J, Montgomery S. Trends in reported babesiosis cases—United States, 2011–2019. MMWR Morb Mortal Wkly Rep. 2023;72:273–7. 10.15585/mmwr.mm7211a1 - DOI - PMC - PubMed
    1. Logan JJ, Hoi AG, Sawada M, Knudby A, Ramsay T, et al. Risk factors for Lyme disease resulting from residential exposure amidst emerging Ixodes scapularis populations: a neighbourhood-level analysis of Ottawa, Ontario. PLoS ONE. 2023;18:e0290463. 10.1371/journal.pone.0290463 - DOI - PMC - PubMed
    1. Thompson JM, Carpenter A, Kersh GJ, Wachs T, Commins SP, Salzer JS. Geographic distribution of suspected alpha-gal syndrome cases—United States, January 2017-December 2022. MMWR Morb Mortal Wkly Rep. 2023;72:815–20. 10.15585/mmwr.mm7230a2 - DOI - PMC - PubMed
    1. Rochlin I, Toledo A. Emerging tick-borne pathogens of public health importance: a mini-review. J Med Microbiol. 2020;69:781–91. 10.1099/jmm.0.001206 - DOI - PMC - PubMed
    1. Gettings JR, Self SCW, McMahan CS, Brown DA, Nordone SK, Yabsley MJ. Local and regional temporal trends (2013–2019) of canine Ehrlichia spp. seroprevalence in the USA. Parasit Vectors. 2020;13:153. 10.1186/s13071-020-04022-4 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources